Introduction Infections caused by parasitic flatworms impose a considerable worldwide
health burden. Recently, World Health Organization launched its roadmap for neglected …

Background: Chemotherapy for schistosomiasis has been around for 100 years. During the
past century, great efforts have been made to develop new antischistosomal drugs from …

Pomegranate (Punica granatum L.) bioactive phenolics have multiple beneficial effects on
human health and play a protective role against many degenerative diseases. Pomegranate …

Praziquantel is the drug of first choice for the treatment of the human schistosomiasis. It is
administered orally, requiring high doses to overcome adverse biopharmaceutical …

Schistosomiasis is a major public health problem worldwide, especially in poor
communities. Since praziquantel is currently the only drug available to treat schistosomiasis …

Triclabendazole is a poorly-water soluble (0.24 μg/mL) compound classified into the Class
II/IV of the Biopharmaceutical Classification System. It is the drug of choice to treat …

Praziquantel is an antiparasitic drug indicated for the treatment of the schistosomiasis
disease. This drug has very low aqueous solubility, requiring high oral doses for its …

Background Schistosomiasis is responsible for a considerable global disease burden. This
work aimed to improve the therapeutic outcome of the only available antischistosomal drug …

Schistosomiasis is a global disease of significant public health relevance. Only one racemic
drug, praziquantel, characterized by low bioavailability, low water solubility and extensive …

Hymenolepiasis represents a parasitic infection of common prevalence in pediatrics with
intimidating impacts, particularly amongst immunocompromised patients. The present work …